ETYQA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ETYQA (ETYQA).
Etyqa is a non-opioid analgesic that modulates sodium channels and inhibits substance P release, reducing pain signaling.
| Metabolism | Primarily metabolized by CYP3A4 and glucuronidation; minor pathways involve CYP2C9 and CYP2D6. |
| Excretion | Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: <10%. |
| Half-life | 12-15 hours in healthy adults; prolonged to 24-30 hours in hepatic impairment. |
| Protein binding | 85-90% primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.5-4.0 L/kg indicating extensive extravascular distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: 1-2 hours; Intravenous: 15-30 minutes. |
| Duration of Action | 8-12 hours with sustained therapeutic effect; may persist longer in overdose. |
ETYQA is not a recognized pharmaceutical agent; no standard dosing information is available.
| Dosage form | TABLET |
| Renal impairment | No data available; insufficient information to provide GFR-based dose modifications. |
| Liver impairment | No data available; insufficient information to provide Child-Pugh based modifications. |
| Pediatric use | No data available; insufficient information to provide weight-based pediatric guidelines. |
| Geriatric use | No data available; insufficient information to provide elderly-specific considerations. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ETYQA (ETYQA).
| Breastfeeding | Excretion into human milk unknown. M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, including renal tubular acidosis, breastfeeding is contraindicated. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show embryotoxicity and teratogenicity at supratherapeutic doses. Second trimester: Risk of fetal growth restriction and oligohydramnios due to placental insufficiency. Third trimester: Neonatal adverse effects including renal impairment, hyperkalemia, and potential for persistent ductus arteriosus closure. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to etyqa or excipients; concomitant use with CYP3A4 strong inducers; severe renal impairment (CrCl <30 mL/min).
| Precautions | Risk of seizures with high doses; avoid in patients with severe hepatic impairment; monitor for dizziness and hypotension. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function (serum creatinine, BUN) and electrolytes (potassium, bicarbonate) monthly. Fetal ultrasound every 4 weeks for growth, amniotic fluid volume, and ductus arteriosus patency. Fetal echocardiography at 20-24 weeks. Neonatal monitoring for hyperkalemia, metabolic acidosis, and renal function. |
| Fertility Effects | Preclinical studies show decreased sperm count and motility in males, and disrupted estrous cycles in females at high doses. Human fertility effects not systematically studied; reversible upon discontinuation. |